Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch
08:25am, Thursday, 11'th Apr 2024
Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the microscope Thursday after the U.S. Department of Justice (DOJ) accused the company of manipulating Medicare's drug pricing reporti
Regeneron Pharma falls after US government alleges fraud
07:48am, Thursday, 11'th Apr 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faced a blow in pre-market trading after being hit with fraud allegations from the US Justice Department. Regeneron allegedly inflated the sales price of it
EXEL or REGN: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 09'th Apr 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks presents investors with the better value o
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
04:05pm, Monday, 01'st Apr 2024
TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursda
Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
02:36pm, Tuesday, 26'th Mar 2024
Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD, competing effectively against biosimilars and Roche's Vabysmo. Libtayo's revenue growth is impressive, w
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
11:41am, Tuesday, 26'th Mar 2024
Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
06:44am, Tuesday, 26'th Mar 2024
As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performanc
US FDA declines to approve Regeneron's blood cancer therapy
07:30am, Monday, 25'th Mar 2024
Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined to approve its blood cancer therapy for two most common subtypes of non-Hodgkin lymphoma due to an issue related to enrollment of its
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
05:07pm, Friday, 22'nd Mar 2024
Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite
US appeals court revives Regeneron's antitrust lawsuit against Novartis
10:16am, Monday, 18'th Mar 2024
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu
Calls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and Nucor
01:20pm, Wednesday, 13'th Mar 2024
The Investment Committee debate the latest calls of the day on a number of stocks.
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
01:36pm, Tuesday, 12'th Mar 2024
Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
01:35pm, Tuesday, 12'th Mar 2024
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
05:52am, Saturday, 09'th Mar 2024
Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.
2 Biotech Stocks to Buy Hand Over Fist in March
08:15am, Friday, 08'th Mar 2024
Regeneron boasts a pair of growth drivers that should still have plenty of fuel left. Exelixis is close to expanding its lineup with a promising late-stage candidate.
